Emergent Biosolutions Total Liabilities 2010-2022 | EBS

Emergent Biosolutions total liabilities from 2010 to 2022. Total liabilities can be defined as the total value of all possible claims against the corporation.
Emergent Biosolutions Annual Total Liabilities
(Millions of US $)
2021 $1,340
2020 $1,436
2019 $1,239
2018 $1,219
2017 $158
2016 $374
2015 $377
2014 $385
2013 $137
2012 $122
2011 $130
2010 $127
2009 $101
Emergent Biosolutions Quarterly Total Liabilities
(Millions of US $)
2022-03-31 $1,205
2021-12-31 $1,340
2021-09-30 $1,345
2021-06-30 $1,372
2021-03-31 $1,377
2020-12-31 $1,436
2020-09-30 $1,365
2020-06-30 $1,267
2020-03-31 $1,204
2019-12-31 $1,239
2019-09-30 $1,299
2019-06-30 $1,332
2019-03-31 $1,166
2018-12-31 $1,219
2018-09-30 $207
2018-06-30 $201
2018-03-31 $187
2017-12-31 $158
2017-09-30 $360
2017-06-30 $350
2017-03-31 $341
2016-12-31 $374
2016-09-30 $384
2016-06-30 $384
2016-03-31 $369
2015-12-31 $377
2015-09-30 $371
2015-06-30 $381
2015-03-31 $380
2014-12-31 $385
2014-09-30 $356
2014-06-30 $349
2014-03-31 $346
2013-12-31 $137
2013-09-30 $129
2013-06-30 $107
2013-03-31 $103
2012-12-31 $122
2012-09-30 $112
2012-06-30 $105
2012-03-31 $103
2011-12-31 $130
2011-09-30 $128
2011-06-30 $113
2011-03-31 $112
2010-12-31 $127
2010-09-30 $87
2010-06-30 $84
2010-03-31 $94
2009-12-31 $101
2009-09-30 $79
2009-06-30 $96
2009-03-31 $91
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.646B $1.793B
Emergent BioSolutions, Inc. is a global specialty biopharmaceutical company offering specialized products to health care providers and governments to combat emerging public health threats. It also supplies vaccines to domestic and international non-government organizations and governments in/ outside of the U.S. BioThrax is the company's key Biodefense product, used for anthrax disease. The U.S. government is the primary purchaser of the company's Biodefense products. It supplies adjuvanted anthrax vaccine candidate, AV7909, to the U.S. government. It supplies smallpox vaccine ACAM2000, botulism therapeutic BAT, anthrax therapeutics 'raxibacumab & Anthrasil' and 3 other products to governments of different countries. It also retails 3 products Narcan nasal spray, Vaxchora and Vivoti. It provides contract development and manufacturing services to multiple pharma and biotech companies. The company has added key products Narcan nasal spray, ACAM2000, raxibacumab, Vaxchora and Vivoti through several acquisitions.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $168.111B 10.23
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.588B 16.71
Biohaven Pharmaceutical Holding (BHVN) United States $10.141B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.081B 0.00
Arcus Biosciences (RCUS) United States $1.832B 46.46
Myovant Sciences (MYOV) United Kingdom $1.264B 0.00
Zymeworks (ZYME) Canada $0.364B 0.00
Gelesis Holdings (GLS) United States $0.116B 0.00
Ambrx Biopharma (AMAM) United States $0.111B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00